Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess the effect of available NRTI backbones in Italy

Trial Profile

To assess the effect of available NRTI backbones in Italy

Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/abacavir (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 New trial record
    • 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top